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Van Os and Reininghaus provide a compelling overview of evidence suggesting that 
psychosis may be perceived as an extreme expression of continuously distributed 
quantitative traits in the general population, where minor psychotic symptoms, similar but 
less severe than those observed in affected individuals can be found in proportions of up to 
7%.  
The concept of the extended psychosis phenotype offers a number of unique opportunities. 
Firstly, recognising the psychosis phenotype as a gradual infusion of quantitative traits into 
clinical syndromes provides an elegant explanation for variation in the degree of severity of 
psychosis-like experiences. Secondly, as highlighted by the authors, the extended psychosis 
phenotype is transdiagnostic in nature, implying that it is not restricted to any specific 
psychotic disorder but rather represents a continuous expression across the psychosis 
spectrum. This may explain the overlap in psychopathological presentation observed across 
mental disorders and therefore provides a foundation for cross-disorder analyses. The latter 
in turn would tackle the indistinctness of current diagnostic categories that are marked by 
lack of clear boundaries between themselves and with normality (1). While considering 
psychopathology in terms of a transdiagnostic psychosis dimension with five specific 
constructs may still be perceived as agnostic with respect to traditional diagnostic systems, 
using these two approaches in combination may allow for a more accurate classification of 
affected individuals. The transdiagnostic approach may also have important advantages for 
scientific research. In research carried out by our group employing the transdiagnostic 
psychosis dimension, a degree of specificity was found in the relationships between different 
types of childhood trauma and psychosis symptom dimensions in adulthood suggesting that 
distinct pathways may be involved in the relationship between the childhood trauma and 
psychosis (2). Eventually, these findings might feed into interventions targeting high-risk 
children. Similarly, Jones et al (3) have demonstrated the importance of the transdiagnostic 
psychosis dimension in exploring how an increased genetic risk for schizophrenia expresses 
during early teens among the general public. Certainly, building on these findings, future 
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studies may shed some light on the pathways between the genetic liability for schizophrenia 
and phenotypical expression of this illness in childhood, adolescence and throughout 
adulthood.  
It is asserted that 20% of those who report subclinical psychotic symptoms make the 
transition to persistent psychosis. If these estimates are accurate, then detecting individuals 
with subclinical psychotic experiences from the general public would offer a unique 
opportunity to reduce the duration of untreated psychosis (DUP), and in turn, improve 
treatment response, risk for relapse and overall prognosis (4). It would also enable early 
interventions ultimately resulting in diminishing symptom severity from the onset; deferring or 
preventing the onset of psychosis and reducing the financial or emotional liabilities 
associated with the lifetime burden of the illness.  
Are these estimates accurate? Identification of individuals with subclinical psychotic 
experiences is reliant on help-seeking behaviour. However, young individuals with an early 
onset of psychosis are less likely to engage in such behaviours (5). The likelihood of help-
seeking is dependent on the awareness and insight of the earliest manifestations of 
psychotic symptoms, and even more so on availability of supportive families and strong 
social networks around at-risk young individuals (5). Another factor arising from the 
calculation of so-called transition rates is the drawing of distinctions between the definition of 
psychotic symptoms (marking the onset of the period of untreated psychosis) and the onset 
of psychotic disorder. The claim that early intervention services reduce the DUP in 
comparison to generic clinical services (6) is critically dependent on whether the time 
between the earliest report of symptoms and the intervention of early intervention services is 
taken as the DUP or, whether the beginning of DUP is ‘reset’ after such an intervention 
unless and until the individual is in the unlucky minority and subsequently develops their first 
episode of full-blown psychosis. Furthermore, preliminary work from our clinic suggests that 
when we look back on the journey that first episode psychosis patients took before arriving 
at such generic catchment area clinical services we find that as a proportion, there are very 
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few who come via prodromal services suggesting that the scope for reducing or postposing 
the onset of psychosis is limited. Some people have an onset that is too rapid and severe 
while others are so insidious that they escape the notice even of services whose philosophy 
is not at all tied to diagnostic categories and who embrace the dimensional approach (7). 
Finally, it has also been argued that subclinical psychotic experiences are more likely to 
occur in adolescence - the phase in young people’s lives that is frequently marked by 
experimenting with substances or rebellious behaviour (1). This issue is exacerbated by 
differing approaches used to elicit psychotic experiences some of which exclude clinical 
judgement and others which seem to lead the respondent into endorsing such experiences 
(see(8) for discussion). These methodological issues probably contribute to the wide range 
of estimates of psychotic experiences in the general population.  
Evidence suggests that neurocognitive alterations, dysregulation in top-down processing and 
reasoning biases may be particularly relevant to the development of psychotic experiences 
even in non-help seeking populations, and sophisticated imaging analysis techniques may 
be used to uncover them (9). These may yet serve as important markers for illness onset. 
However, it is too early to say how specific these sorts of findings are to psychotic spectrum 
disorders and to what extent they apply to other mental disorders. Certainly, the evidence, 
based on family studies suggests that subclinical psychotic experiences are influenced by 
genetic risk factors. In theory this may offer a unique prospect to develop a screening test 
based on genetic composition. Indeed, similarly to the asserted nature of the extended 
psychosis phenotype, the genetic risk for psychosis is distributed on a continuum at the 
highest end of which are affected individuals followed by their healthy relatives (10). 
Although, these results support the premise of being able to detect those at risk based on 
their genetic make-up, recent attempts of linking genetic risk score for schizophrenia to an 
intermediate phenotype in non-clinical populations have so far been contradictory (11). 
The importance of the transdiagnostic and extended psychosis phenotype in relation to 
diagnosis, aetiology, prevalence and outlining the future direction for research are indeed 
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noteworthy. However, without a clearly established and scientifically validated threshold 
defining pathology as well as markers indicative of susceptibility to the illness, the borderline 
between normality and psychopathology will remain contested. 
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